Alterations in Acylcarnitines, Amines, and Lipids Inform about Mechanism of Action of Citalopram/Escitalopram in Major Depression
Ahmed T. Ahmed,
Michelle K. Skime,
Lisa St. John-Williams,
M. Arthur Moseley,
J. Will Thompson,
W. Edward Craighead,
A. John Rush,
Mark A Frye,
Boadie W. Dunlop,
Richard M. Weinshilboum,
The Mood Disorders Precision Medicine Consortium (MDPMC),
Posted 10 Feb 2020
bioRxiv DOI: 10.1101/2020.02.10.927012
Posted 10 Feb 2020
Selective serotonin reuptake inhibitors (SSRIs) are the first line treatment for major depressive disorder (MDD), yet their mechanisms of action are not fully understood and their therapeutic benefit varies among individuals. We used a targeted metabolomics approach utilizing a panel of 180 metabolites to gain insights into mechanisms of action and response to citalopram/escitalopram. Plasma samples from 136 participants with MDD enrolled into the Mayo Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) were profiled at baseline and after 8 weeks of treatment. After treatment, we saw increased levels of short chain acylcarnitines and decreased levels of medium and long chain acylcarnitines, suggesting an SSRI effect on β-oxidation and mitochondrial function. Amines including arginine, proline, and methionine sulfoxide were upregulated while serotonin and sarcosine were downregulated, suggesting an SSRI effect on urea cycle, one-carbon metabolism and serotonin uptake. Eighteen lipids within the phosphatidylcholine (PC aa and ae) classes were upregulated. Changes in several lipid and amine levels correlated with changes in 17 item Hamilton Rating Scale for Depression scores (HRSD17). Differences in metabolic profiles at baseline and post-treatment were noted between participants who remitted (HRSD17≤7) and those who gained no meaningful benefits (<30% reduction in HRSD17). Remitters exhibited a) higher baseline levels of C3, C5, alpha-aminoadipic acid, sarcosine and serotonin; and b) higher week-8 levels of PC aa C34:1, PC aa C34:2, PC aa C36:2 and PC aa C36:4. These findings suggest that mitochondrial energetics including acylcarnitine metabolism, transport and its link to β-oxidation and lipid membrane remodeling may play roles in SSRI treatment response.
- Downloaded 318 times
- Download rankings, all-time:
- Site-wide: 67,873 out of 117,931
- In neuroscience: 10,580 out of 18,544
- Year to date:
- Site-wide: 24,402 out of 117,931
- Since beginning of last month:
- Site-wide: 20,618 out of 117,931
Downloads over time
Distribution of downloads per paper, site-wide
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!